The new influenza A (H1N1) viruses currently susceptible to the neuraminidase inhibitors (NAIs) Oseltamivir and Zanamivir
Early administration of NAIs
may reduce severity and duration of illness
may also contribute to prevent progression to severe disease and death
Antiviral therapy will be beneficial specially for
pregnant patients, in whom administration of antiviral medicines should be carefully evaluated taking possible benefits and risks into consideration
patients with progressing lower respiratory disease or pneumonia
patients with underlying medical conditions.
If used, antiviral treatment should ideally be started early, but it may also be used at any stage of active disease when ongoing viral replication is anticipated as it is possible that the virus may replicate for a prolonged period of time in some patients as a result of the lack of pre-existing protective immunity
WHO received the first report of an Oseltamivir-resistant pandemic virus in July
The number of these events has been steadily increasing, in line with recent increases in influenza activity in many parts of the world and a corresponding increase in the administration of antiviral drugs
Recently, the number of documented cases of Oseltamivir resistance in H1N1 viruses has risen from 57 to 96
Around one third of these cases occurred in patients whose immune systems were severely suppressed
by haematological malignancy
aggressive chemotherapy for cancer
or post-transplant treatment.
WHO recommends vigilant monitoring for the development of Oseltamivir-resistant viruses and for any changes in the transmissibility or pathogenicity of these viruses.
Limiting travel and imposing travel restrictions would have very little effect on stopping the virus from spreading, but would be highly disruptive to the community.
Although identifying signs and symptoms of influenza in travellers can help track the path of the outbreak, it will not reduce the spread of influenza, as the virus can be transmitted from person to person before the onset of symptoms.
WHO do not believe that entry and exit screenings would work to reduce the spread of this disease.
People who are ill should delay travel plans.
Returning travellers who become ill should contact their health care provider.
Travellers can protect themselves and others by following simple prevention practices that apply while travelling and in daily life.
WHO is coordinating the distribution of donated pandemic influenza vaccine to 95 countries with immediate focus on 35 countries. These countries were identified based on their vulnerability to pandemic influenza and their readiness and ability to use the vaccine for priority populations.
WHO has received pledges of nearly 180 million doses of vaccine, 75 million syringes and US$ 67 million for vaccine deployment.
34 of the first 35 countries have requested vaccine donations.
20 countries have signed agreements with WHO.
4 countries have finalized national deployment plans.
More than 100,000 persons have been tested for Influenza A (H1N1) in government laboratories and a few private Laboratories across the country till mid - December
More than 23,000 positive cases reported
More than 750 deaths
More than 30 % deaths from state of Maharashtra
Recent cases are more from northern part of the country
Lab-confirmed Cases reported to WHO As on 22 nd November 2009 * Given that countries are no longer required to test and report individual cases, the number of cases reported actually understates the real number of cases. ** The total number of cases are no longer reported from these regions Over 622482 Total …… 176796 WHO Regional Office for the Western Pacific (WPRO) 47059 WHO Regional Office for South-East Asia (SEARO) Over 154000 WHO Regional Office for Europe (EURO)** 38359 WHO Regional Office for the Eastern Mediterranean (EMRO) 190765 WHO Regional Office for the Americas (AMRO)** 15503 WHO Regional Office for Africa (AFRO) Cases* Region
CDC Estimates of 2009 H1N1 Cases and Related Hospitalizations and Deaths in US from April-November 14 By Age Group
Lab-confirmed Deaths reported to WHO As on 20 th December 2009 * The reported number of fatal cases is an under representation of the actual numbers as many deaths are never tested or recognized as influenza related. At least 11516 Total…… 1039 WHO Regional Office for the Western Pacific (WPRO) 990 WHO Regional Office for South-East Asia (SEARO) At least 2045 WHO Regional Office for Europe (EURO) 663 WHO Regional Office for the Eastern Mediterranean (EMRO) At least 6670 WHO Regional Office for the Americas (AMRO) 109 WHO Regional Office for Africa (AFRO) Deaths* Region